Trial Profile
Phase Ia Pharmacokinetic and Tolerability Study of Oral NV-27 in Normal Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs NV 27 (Primary)
- Indications Coronary artery restenosis
- Focus Pharmacokinetics
- Sponsors Kazia Therapeutics; Novogen
- 17 Nov 2017 According to a Kazia Therapeutics media release, Novogen changed its name to Kazia Therapeutics.
- 14 May 2009 New trial record